Politwoops
Explore the Tweets They Didn't Want You to See
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office.
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office. If you think we're missing someone, please email us with their name, state, political party, office they hold or are seeking and, of course, their Twitter handle.
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.
SteveFDA (R-D.C.)
@SGottliebFDA
As more drugs are being approved under the accelerated approval pathway and we make more robust use of accelerated approval, as a way to advance promising medicines for serious diseases, it’s important to update our regulatory recommendations for how these products are labeled.
SteveFDA (R-D.C.)
@SGottliebFDA
We’re taking new steps to help ensure a product’s labeling provides actionable, complete information about the clinical evidence supporting these accelerated approvals and clearly states the post-market commitments that may have to be met for an indication to remain approved.
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is committed to making sure that health care providers have accurate, actionable information about prescription medications, so that patients and providers can make the most informed decisions about a drug’s risks and benefits.
RT @cubanlefse: Thank you @RepDonBacon staffer and chief of staff, for meeting with us on behalf of @SSFFoundation16 and @uscgcpoa and talking to us about #PayOurCoasties #teamUSCGhHillDay https://t.co/6YfzcisFN4
SteveFDA (R-D.C.)
@SGottliebFDA
New article from @NatRevClinOncol highlights @FDAOncology work in 2018, a year of many drug-related firsts for #FDA and record novel drug approvals. Many will have a significant impact on improving health. https://t.co/3etd8yvohp QT @NatRevClinOncol: )
SteveFDA (R-D.C.)
@SGottliebFDA
In 2018, #FDA set and broke records for novel drug approvals. ICYMI: #FDAVoices posted earlier this month highlights the innovative regulatory tools used to enhance efficiency and expedite the review and approval of drugs. https://t.co/AhBDbbp23R
SteveFDA (R-D.C.)
@SGottliebFDA
@dgingery We'll be continuing high-risk inspections of compounding facilities. It will be excepted work, meaning our dedicated inspectors will not be paid for these assignments during the funding lapse, but compounding inspection work continues.
SteveFDA (R-D.C.)
@SGottliebFDA
RT @califf001: This makes me homesick. Just passed my 2 year "cooling off" period. Best wishes to the hard working FDA workforce. The American public depends on you, so keep the faith! https://t.co/qJtZzlVTpg
Duffy4Wisconsin (R-Wis.)
@Duffy4Wisconsin
RT @RepSeanDuffy: Happy National #SchoolChoice Week! Did you know that more than 2 in 3 Americans support school choice? (Source @WILawLiberty) https://t.co/x1ZljRYp1R
SteveFDA (R-D.C.)
@SGottliebFDA
RT @dgingery: Compounding Inspections continue despite lack of user fee funding... https://t.co/n58IDlryHR
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.